Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renier Brentjens

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Hematological Oncology|June 13, 2019
CAR T-cell therapy: Full speed aheadDavid Sermer, Renier Brentjens
Science (New York, N.Y.)|December 5, 2024
Synthetic gene circuits drive disease-fighting T cellsMarco L Davila, Renier Brentjens
Hematology/Oncology Clinics of North America|April 9, 2013
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?Marco L Davila, Renier Brentjens
Best Practice & Research. Clinical Haematology|June 19, 2018
CAR T cells, immunologic and cellular therapies in hematologic malignanciesRenier Brentjens, Marco L Davila
Methods in Molecular Biology (Clifton, N.J.)|December 27, 2008
Retroviral transduction of murine primary T lymphocytesJames Lee, Michel Sadelain, Renier Brentjens
Cancer Discovery|April 4, 2013
The basic principles of chimeric antigen receptor designMichel Sadelain, Renier Brentjens, Isabelle Rivière
Current Opinion in Immunology|March 31, 2009
The promise and potential pitfalls of chimeric antigen receptorsMichel Sadelain, Renier Brentjens, Isabelle Rivière
Nature Reviews. Cancer|January 2, 2003
Targeting tumours with genetically enhanced T lymphocytesMichel Sadelain, Isabelle Rivière, Renier Brentjens
Hematology/Oncology Clinics of North America|November 19, 2011
Cellular therapies in acute lymphoblastic leukemiaJae H Park, Craig Sauter, Renier Brentjens
Cancer Journal (Sudbury, Mass.)|November 21, 2015
CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to DateMarco L Davila, Craig Sauter, Renier Brentjens
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Hematological Oncology|June 13, 2019
CAR T-cell therapy: Full speed aheadDavid Sermer, Renier Brentjens
Science (New York, N.Y.)|December 5, 2024
Synthetic gene circuits drive disease-fighting T cellsMarco L Davila, Renier Brentjens
Hematology/Oncology Clinics of North America|April 9, 2013
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?Marco L Davila, Renier Brentjens
Best Practice & Research. Clinical Haematology|June 19, 2018
CAR T cells, immunologic and cellular therapies in hematologic malignanciesRenier Brentjens, Marco L Davila
Methods in Molecular Biology (Clifton, N.J.)|December 27, 2008
Retroviral transduction of murine primary T lymphocytesJames Lee, Michel Sadelain, Renier Brentjens
Cancer Discovery|April 4, 2013
The basic principles of chimeric antigen receptor designMichel Sadelain, Renier Brentjens, Isabelle Rivière
Current Opinion in Immunology|March 31, 2009
The promise and potential pitfalls of chimeric antigen receptorsMichel Sadelain, Renier Brentjens, Isabelle Rivière
Nature Reviews. Cancer|January 2, 2003
Targeting tumours with genetically enhanced T lymphocytesMichel Sadelain, Isabelle Rivière, Renier Brentjens
Hematology/Oncology Clinics of North America|November 19, 2011
Cellular therapies in acute lymphoblastic leukemiaJae H Park, Craig Sauter, Renier Brentjens
Cancer Journal (Sudbury, Mass.)|November 21, 2015
CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to DateMarco L Davila, Craig Sauter, Renier Brentjens
Pageof 3